Discontinued — last reported Q4 '25
Cash & Equivalents
Current AssetsEli Lilly Cash & Equivalents decreased by 25.8% to $7.27B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 122.4%, from $3.27B to $7.27B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 14.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and the ability to fund operations or acquisitions without debt; a decrease may indicate heavy capital expenditure or shareholder returns.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term instruments with matu...
Peer comparison
Peer tech giants like Alphabet or Apple maintain massive cash reserves to navigate market volatility and fund R&D.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.22B | $3.79B | $3.82B | $2.46B | $2.62B | $2.62B | $2.07B | $3.55B | $2.69B | $2.38B | $2.82B | $2.46B | $3.22B | $3.37B | $3.27B | $3.09B | $3.38B | $9.79B | $7.27B |
| QoQ Change | — | +17.6% | +0.8% | -35.6% | +6.7% | -0.2% | -21.0% | +71.5% | -24.0% | -11.6% | +18.4% | -12.7% | +31.0% | +4.5% | -3.0% | -5.4% | +9.1% | +190.1% | -25.8% |
| YoY Change | — | — | — | — | -18.5% | -30.9% | -45.9% | +44.2% | +2.7% | -9.0% | +36.4% | -30.6% | +19.6% | +41.5% | +16.0% | +25.7% | +4.7% | +190.6% | +122.4% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Eli Lilly's cash & equivalents?
- Eli Lilly (LLY) reported cash & equivalents of $7.27B in Q4 2025.
- How has Eli Lilly's cash & equivalents changed year-over-year?
- Eli Lilly's cash & equivalents increased by 122.4% year-over-year, from $3.27B to $7.27B.
- What is the long-term trend for Eli Lilly's cash & equivalents?
- Over 5 years (2020 to 2025), Eli Lilly's cash & equivalents has grown at a 14.7% compound annual growth rate (CAGR), from $3.66B to $7.27B.
- What does cash & equivalents mean?
- Money in the bank and investments that can be turned into cash almost instantly.